Findings in our study are expected to provide evidence for understanding the characteristics of breast cancer with low HER2 expression and guide the selection of an adjuvant chemotherapy scheme for early-stage breast cancer with low HER2 expression. This evidence concerns the gene ERBB2 and breast cancer.